研究目的:射血分数保留型心力衰竭(HFpEF)的病因复杂且临床表型差异较大,多数HFpEF患者伴有超重或肥胖,且专门针对HFpEF肥胖表型的治疗方案目前尚无定论。STEP-HFpEF研究旨在评估一周一次司美格鲁肽(2.4 mg)或安慰剂对HFpEF伴体重指数(BMI)≥...
HFpEF病因存在高度异质性,其中,肥胖是引起HFpEF发生及发展的重要危险因素之一 ;现有心衰相关指南/共识等均强调,对于HFpEF患者存在的肥胖应给予充分关注、监测及管理3,而HFpEF的肥胖表型也存在特有的血流动力学特征4,因此,在常规心衰的管理策...
[1] Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. STEP-HFpEF Trial Committees and Investigators. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023 Aug 25. doi: 10.1056/NEJMoa2306963. [2] Borlaug BA, Kitzman DW, Davies MJ, ...
[1] Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. STEP-HFpEF Trial Committees and Investigators. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023 Aug 25. doi: 10.1056/NEJMoa2306963. [2] Borlaug BA, Kitzman DW, Davies MJ, ...
STEP-HFpEF研究纳入了射血分数保留型心衰(HFpEF)合并肥胖的患者,评估一周一次注射用司美格鲁肽(2.4mg)的临床疗效。研究结果显示,司美格鲁肽表现了预期的减重效果,同时改善了心衰相关症状和身体功能。 今天的文章,菌菌将简析STEP-HFpEF研究结果,重点聚焦在研究的主要终点和验证性次要终点。 一、STEP-HFpEF研究背景 射...
Similar trials were conducted with empagliflozin in HFrEF and HFpEF patients: the EMPEROR-Reduced and the ongoing EMPEROR-Preserved trials.4, 14 DAPA-HF was an international, multicenter, phase 3, placebo-controlled trial in patients with chronic HF, with or without T2D, randomized to receive ...
[1] Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. STEP-HFpEF Trial Committees and Investigators. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023 Aug 25. doi: 10.1056/NEJMoa2306963. ...